JP2024504392A5 - - Google Patents
Info
- Publication number
- JP2024504392A5 JP2024504392A5 JP2023544450A JP2023544450A JP2024504392A5 JP 2024504392 A5 JP2024504392 A5 JP 2024504392A5 JP 2023544450 A JP2023544450 A JP 2023544450A JP 2023544450 A JP2023544450 A JP 2023544450A JP 2024504392 A5 JP2024504392 A5 JP 2024504392A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- composition according
- form iii
- section
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163141789P | 2021-01-26 | 2021-01-26 | |
| US63/141,789 | 2021-01-26 | ||
| PCT/US2022/013953 WO2022164941A1 (en) | 2021-01-26 | 2022-01-26 | Advantageous morphic form of at-527 hemi-sulfate salt |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024504392A JP2024504392A (ja) | 2024-01-31 |
| JP2024504392A5 true JP2024504392A5 (enExample) | 2025-01-29 |
Family
ID=82653876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023544450A Pending JP2024504392A (ja) | 2021-01-26 | 2022-01-26 | Ａｔ－５２７ヘミ硫酸塩の有利な形態 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20230365611A1 (enExample) |
| EP (1) | EP4284389A4 (enExample) |
| JP (1) | JP2024504392A (enExample) |
| KR (1) | KR20230135635A (enExample) |
| CN (1) | CN116744939A (enExample) |
| AU (1) | AU2022213335A1 (enExample) |
| BR (1) | BR112023014825A2 (enExample) |
| CA (1) | CA3173656A1 (enExample) |
| IL (1) | IL304402A (enExample) |
| MX (1) | MX2023008746A (enExample) |
| TW (1) | TW202245806A (enExample) |
| WO (1) | WO2022164941A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110248951B (zh) | 2017-02-01 | 2022-10-28 | 阿堤亚制药公司 | 用于治疗丙型肝炎病毒的核苷酸半硫酸盐 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| AU2022213335A1 (en) * | 2021-01-26 | 2023-07-27 | Atea Pharmaceuticals, Inc. | Advantageous morphic form of at-527 hemi-sulfate salt |
| BR112023026356A2 (pt) | 2021-06-17 | 2024-03-05 | Atea Pharmaceuticals Inc | Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c |
| WO2024211746A1 (en) * | 2023-04-06 | 2024-10-10 | Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center | Treatment of autoimmune diseases and cancer with protease inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20217282B (en) | 2015-03-06 | 2021-08-10 | Atea Pharmaceuticals Inc | β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT |
| PT3512863T (pt) | 2016-09-07 | 2022-03-09 | Atea Pharmaceuticals Inc | Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna |
| US20180214370A1 (en) * | 2017-01-31 | 2018-08-02 | L'oreal | Topcoat for long-wear lip compositions |
| CN110248951B (zh) | 2017-02-01 | 2022-10-28 | 阿堤亚制药公司 | 用于治疗丙型肝炎病毒的核苷酸半硫酸盐 |
| WO2019200005A1 (en) * | 2018-04-10 | 2019-10-17 | Atea Pharmaceuticals, Inc. | Treatment of hcv infected patients with cirrhosis |
| WO2020117966A1 (en) * | 2018-12-05 | 2020-06-11 | Atea Pharmaceuticals, Inc. | Highly active drug combination for treatment of hepatitis c virus |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| AU2022213335A1 (en) * | 2021-01-26 | 2023-07-27 | Atea Pharmaceuticals, Inc. | Advantageous morphic form of at-527 hemi-sulfate salt |
-
2022
- 2022-01-26 AU AU2022213335A patent/AU2022213335A1/en active Pending
- 2022-01-26 CN CN202280011806.3A patent/CN116744939A/zh active Pending
- 2022-01-26 TW TW111103408A patent/TW202245806A/zh unknown
- 2022-01-26 MX MX2023008746A patent/MX2023008746A/es unknown
- 2022-01-26 WO PCT/US2022/013953 patent/WO2022164941A1/en not_active Ceased
- 2022-01-26 EP EP22746553.1A patent/EP4284389A4/en active Pending
- 2022-01-26 CA CA3173656A patent/CA3173656A1/en active Pending
- 2022-01-26 JP JP2023544450A patent/JP2024504392A/ja active Pending
- 2022-01-26 BR BR112023014825A patent/BR112023014825A2/pt unknown
- 2022-01-26 KR KR1020237028660A patent/KR20230135635A/ko active Pending
-
2023
- 2023-07-11 IL IL304402A patent/IL304402A/en unknown
- 2023-07-25 US US18/226,064 patent/US20230365611A1/en active Pending
-
2025
- 2025-10-06 US US19/350,713 patent/US20260035404A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI902264B (zh) | {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式，其組合物及用途 | |
| ES2326529T3 (es) | Composicion farmaceutica que contiene una forma amorfa estabilizada de clorhidrato de donepezil. | |
| CN105646584B (zh) | 替诺福韦艾拉酚胺富马酸盐晶型及其制备方法和用途 | |
| JP2023524599A5 (enExample) | ||
| JP2019509268A5 (enExample) | ||
| CN101918418A (zh) | 替诺福韦地索普西的固体形式 | |
| CN1970547B (zh) | 非布司他的晶型及其制备方法 | |
| JP2012507496A (ja) | レナリドマイドの結晶形およびその調製方法 | |
| CN102002035A (zh) | 甲磺酸伊马替尼的δ和ε晶形 | |
| CN101633662A (zh) | 普拉格雷的药用酸加成盐及其制备方法和药物应用 | |
| CN101712692A (zh) | 泰诺福韦酯的药用酸加成盐及其制备方法和药物应用 | |
| JP2005530787A5 (enExample) | ||
| KR20220060488A (ko) | 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산의 결정성 입자의 제조방법 및 이를 포함하는 약학적 조성물 | |
| US6717015B2 (en) | Venlafaxine besylate | |
| JP2023536667A5 (enExample) | ||
| RU2004127585A (ru) | Кристаллическая натриевая соль парекоксиба | |
| WO2016078543A1 (zh) | 一种盐酸洛氟普啶多晶型物及其制备方法 | |
| JP2010540470A5 (enExample) | ||
| WO2006087732A1 (en) | An amorphous and three crystalline forms of rimonabant hydrochloride | |
| JP2023548855A5 (enExample) | ||
| CN104628708A (zh) | 一种阿伐那非的晶型及其制备方法、用途和药物组合物 | |
| SI22543A (sl) | Nove soli perindoprila | |
| JP2025511126A5 (enExample) | ||
| WO2020161654A1 (en) | A process for the preparation of trametinib acetic acid solvate | |
| WO2007131444A1 (fr) | Nouvelle forme cristallographique du composé 3,4',5-trihydroxyl-stilbène-3-bêta-d-glucoside |